Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 1
1947 2
1948 3
1949 3
1950 3
1951 1
1952 11
1953 7
1954 9
1955 6
1956 3
1957 3
1958 9
1959 7
1960 7
1961 8
1962 5
1963 4
1964 8
1965 8
1966 1
1967 3
1968 4
1969 13
1970 1
1971 14
1972 14
1973 13
1974 13
1975 8
1976 4
1977 10
1978 4
1979 9
1980 10
1981 7
1982 11
1983 4
1984 10
1985 9
1986 13
1987 16
1988 15
1989 20
1990 23
1991 21
1992 23
1993 18
1994 33
1995 29
1996 28
1997 27
1998 54
1999 43
2000 47
2001 83
2002 118
2003 146
2004 133
2005 127
2006 140
2007 172
2008 181
2009 238
2010 222
2011 278
2012 245
2013 316
2014 319
2015 279
2016 346
2017 351
2018 375
2019 307
2020 397
2021 402
2022 410
2023 431
2024 156

Text availability

Article attribute

Article type

Publication date

Search Results

6,022 results

Results by year

Filters applied: . Clear all
Page 1
Assessment of Cardiovascular Disease Risk: A 2022 Update.
Goldsborough E 3rd, Osuji N, Blaha MJ. Goldsborough E 3rd, et al. Endocrinol Metab Clin North Am. 2022 Sep;51(3):483-509. doi: 10.1016/j.ecl.2022.02.005. Epub 2022 Jul 4. Endocrinol Metab Clin North Am. 2022. PMID: 35963625 Review.
Assessment of atherosclerotic cardiovascular disease (ASCVD) risk is the cornerstone of primary ASCVD prevention, enabling targeted use of the most aggressive therapies in those most likely to benefit, while guiding a conservative approach in those who are low risk. …
Assessment of atherosclerotic cardiovascular disease (ASCVD) risk is the cornerstone of primary ASCVD prevention, enabling targeted u …
Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement.
Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, Dweck MR, Koschinsky M, Lambert G, Mach F, McNeal CJ, Moriarty PM, Natarajan P, Nordestgaard BG, Parhofer KG, Virani SS, von Eckardstein A, Watts GF, Stock JK, Ray KK, Tokgözoğlu LS, Catapano AL. Kronenberg F, et al. Eur Heart J. 2022 Oct 14;43(39):3925-3946. doi: 10.1093/eurheartj/ehac361. Eur Heart J. 2022. PMID: 36036785 Free PMC article.
Lipoprotein apheresis is an option for very high Lp(a) with progressive cardiovascular disease despite optimal management of risk factors. In conclusion, this statement reinforces evidence for Lp(a) as a causal risk factor for cardiovascular outcomes. Trials of specific Lp …
Lipoprotein apheresis is an option for very high Lp(a) with progressive cardiovascular disease despite optimal management of risk fac …
Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement.
Neeland IJ, Ross R, Després JP, Matsuzawa Y, Yamashita S, Shai I, Seidell J, Magni P, Santos RD, Arsenault B, Cuevas A, Hu FB, Griffin B, Zambon A, Barter P, Fruchart JC, Eckel RH; International Atherosclerosis Society; International Chair on Cardiometabolic Risk Working Group on Visceral Obesity. Neeland IJ, et al. Lancet Diabetes Endocrinol. 2019 Sep;7(9):715-725. doi: 10.1016/S2213-8587(19)30084-1. Epub 2019 Jul 10. Lancet Diabetes Endocrinol. 2019. PMID: 31301983 Free article. Review.
This joint position statement from the International Atherosclerosis Society and the International Chair on Cardiometabolic Risk Working Group on Visceral Obesity summarises the evidence for visceral adiposity and ectopic fat as emerging risk factors for type 2 diabetes, atherosc …
This joint position statement from the International Atherosclerosis Society and the International Chair on Cardiometabolic Risk Working Gro …
Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention.
Wong ND, Sattar N. Wong ND, et al. Nat Rev Cardiol. 2023 Oct;20(10):685-695. doi: 10.1038/s41569-023-00877-z. Epub 2023 May 16. Nat Rev Cardiol. 2023. PMID: 37193856 Review.
Secular changes in CVD outcomes have occurred over the past few decades, mainly due to a decline in the incidence of ischaemic heart disease. The onset of T2DM at a young age (<40 years), leading to a greater number of life-years lost, has also become increasingly commo …
Secular changes in CVD outcomes have occurred over the past few decades, mainly due to a decline in the incidence of ischaemic heart dise …
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery.
Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, Granger CB, Lange RA, Mack MJ, Mauri L, Mehran R, Mukherjee D, Newby LK, O'Gara PT, Sabatine MS, Smith PK, Smith SC Jr. Levine GN, et al. Circulation. 2016 Sep 6;134(10):e123-55. doi: 10.1161/CIR.0000000000000404. Epub 2016 Mar 29. Circulation. 2016. PMID: 27026020 Review. No abstract available.
Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline.
LeRoith D, Biessels GJ, Braithwaite SS, Casanueva FF, Draznin B, Halter JB, Hirsch IB, McDonnell ME, Molitch ME, Murad MH, Sinclair AJ. LeRoith D, et al. J Clin Endocrinol Metab. 2019 May 1;104(5):1520-1574. doi: 10.1210/jc.2019-00198. J Clin Endocrinol Metab. 2019. PMID: 30903688 Free PMC article.
CONCLUSIONS: Diabetes, particularly type 2, is becoming more prevalent in the general population, especially in individuals over the age of 65 years. The underlying pathophysiology of the disease in these patients is exacerbated by the direct effects of aging on metabolic …
CONCLUSIONS: Diabetes, particularly type 2, is becoming more prevalent in the general population, especially in individuals over the age of …
International Expert Consensus Document on Takotsubo Syndrome (Part I): Clinical Characteristics, Diagnostic Criteria, and Pathophysiology.
Ghadri JR, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi YJ, Cammann VL, Crea F, Galiuto L, Desmet W, Yoshida T, Manfredini R, Eitel I, Kosuge M, Nef HM, Deshmukh A, Lerman A, Bossone E, Citro R, Ueyama T, Corrado D, Kurisu S, Ruschitzka F, Winchester D, Lyon AR, Omerovic E, Bax JJ, Meimoun P, Tarantini G, Rihal C, Y-Hassan S, Migliore F, Horowitz JD, Shimokawa H, Lüscher TF, Templin C. Ghadri JR, et al. Eur Heart J. 2018 Jun 7;39(22):2032-2046. doi: 10.1093/eurheartj/ehy076. Eur Heart J. 2018. PMID: 29850871 Free PMC article.
Takotsubo syndrome (TTS) is a poorly recognized heart disease that was initially regarded as a benign condition. Recently, it has been shown that TTS may be associated with severe clinical complications including death and that its prevalence is probably underestimated. .. …
Takotsubo syndrome (TTS) is a poorly recognized heart disease that was initially regarded as a benign condition. Recently, it has bee …
2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance.
Cuchel M, Raal FJ, Hegele RA, Al-Rasadi K, Arca M, Averna M, Bruckert E, Freiberger T, Gaudet D, Harada-Shiba M, Hudgins LC, Kayikcioglu M, Masana L, Parhofer KG, Roeters van Lennep JE, Santos RD, Stroes ESG, Watts GF, Wiegman A, Stock JK, Tokgözoğlu LS, Catapano AL, Ray KK. Cuchel M, et al. Eur Heart J. 2023 Jul 1;44(25):2277-2291. doi: 10.1093/eurheartj/ehad197. Eur Heart J. 2023. PMID: 37130090 Free PMC article.
The statement also provides state-of-the art discussion and guidance to clinicians for interpreting the results of genetic testing and for family planning and pregnancy. Therapeutic decisions are based on the LDL-C level. Combination LDL-C-lowering therapy-both phar …
The statement also provides state-of-the art discussion and guidance to clinicians for interpreting the results of genetic testing and for f …
Towards clinical utility of polygenic risk scores.
Lambert SA, Abraham G, Inouye M. Lambert SA, et al. Hum Mol Genet. 2019 Nov 21;28(R2):R133-R142. doi: 10.1093/hmg/ddz187. Hum Mol Genet. 2019. PMID: 31363735 Review.
Prediction of disease risk is an essential part of preventative medicine, often guiding clinical management. ...In this review, we summarize the potential use cases for seven common diseases (breast cancer, prostate cancer, coronary artery disease, obesity, type 1 d …
Prediction of disease risk is an essential part of preventative medicine, often guiding clinical management. ...In this review, we su …
6,022 results